These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 29940558)

  • 1. Harmonization of the Genetic Code Effectively Enhances the Recombinant Production of the Major Birch Pollen Allergen Bet v 1.
    Asam C; Roulias A; Parigiani MA; Haab A; Wallner M; Wolf M; Briza P; Bohle B; Ferreira F; Hauser M
    Int Arch Allergy Immunol; 2018; 177(2):116-122. PubMed ID: 29940558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folded or Not? Tracking Bet v 1 Conformation in Recombinant Allergen Preparations.
    Husslik F; Hanschmann KM; Krämer A; Seutter von Loetzen C; Schweimer K; Bellinghausen I; Treudler R; Simon JC; Vogel L; Völker E; Randow S; Reuter A; Rösch P; Vieths S; Holzhauser T; Schiller D
    PLoS One; 2015; 10(7):e0132956. PubMed ID: 26186356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.
    Batard T; Didierlaurent A; Chabre H; Mothes N; Bussières L; Bohle B; Couret MN; Ball T; Lemoine P; Focks Tejkl M; Chenal A; Clément G; Dupont F; Valent P; Krauth MT; André C; Valenta R; Moingeon P
    Int Arch Allergy Immunol; 2005 Mar; 136(3):239-49. PubMed ID: 15722633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
    Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
    Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
    Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
    Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
    Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model system to study the environment-dependent expression of the Bet v 1a gene encoding the major birch pollen allergen.
    Tashpulatov AS; Clement P; Akimcheva SA; Belogradova KA; Barinova I; Rakhmawaty FD; Heberle-Bors E; Touraev A
    Int Arch Allergy Immunol; 2004 May; 134(1):1-9. PubMed ID: 15051934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular composition and biological activity of commercial birch pollen allergen extracts.
    Focke M; Marth K; Valenta R
    Eur J Clin Invest; 2009 May; 39(5):429-36. PubMed ID: 19302561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of recombinant T1, a non-allergenic periwinkle (Catharanthus roseus) protein, with sequence similarity to the Bet v 1 plant allergen family.
    Laffer S; Hamdi S; Lupinek C; Sperr WR; Valent P; Verdino P; Keller W; Grote M; Hoffmann-Sommergruber K; Scheiner O; Kraft D; Rideau M; Valenta R
    Biochem J; 2003 Jul; 373(Pt 1):261-9. PubMed ID: 12656672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The conformational IgE epitope profile of soya bean allergen Gly m 4.
    Husslik F; Nürnberg J; Seutter von Loetzen C; Mews T; Ballmer-Weber BK; Kleine-Tebbe J; Treudler R; Simon JC; Randow S; Völker E; Reuter A; Rösch P; Vieths S; Holzhauser T; Schiller D
    Clin Exp Allergy; 2016 Nov; 46(11):1484-1497. PubMed ID: 27533495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy.
    Mittag D; Akkerdaas J; Ballmer-Weber BK; Vogel L; Wensing M; Becker WM; Koppelman SJ; Knulst AC; Helbling A; Hefle SL; Van Ree R; Vieths S
    J Allergy Clin Immunol; 2004 Dec; 114(6):1410-7. PubMed ID: 15577846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
    Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
    Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1.
    Gieras A; Cejka P; Blatt K; Focke-Tejkl M; Linhart B; Flicker S; Stoecklinger A; Marth K; Drescher A; Thalhamer J; Valent P; Majdic O; Valenta R
    J Immunol; 2011 May; 186(9):5333-44. PubMed ID: 21451110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
    J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
    Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
    Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
    Larenas-Linnemann D
    Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization.
    Movérare R; Westritschnig K; Svensson M; Hayek B; Bende M; Pauli G; Sorva R; Haahtela T; Valenta R; Elfman L
    Int Arch Allergy Immunol; 2002 Aug; 128(4):325-35. PubMed ID: 12218371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and implication of an allergenic PR-10 protein from walnut in birch pollen associated walnut allergy.
    Wangorsch A; Jamin A; Lidholm J; Gräni N; Lang C; Ballmer-Weber B; Vieths S; Scheurer S
    Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 28070926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cor a 1-reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen-associated food allergy to hazelnut.
    Hofmann C; Scheurer S; Rost K; Graulich E; Jamin A; Foetisch K; Saloga J; Vieths S; Steinbrink K; Adler HS
    J Allergy Clin Immunol; 2013 May; 131(5):1384-92.e6. PubMed ID: 23246018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients.
    Nony E; Bouley J; Le Mignon M; Lemoine P; Jain K; Horiot S; Mascarell L; Pallardy M; Vincentelli R; Leone P; Roussel A; Batard T; Abiteboul K; Robin B; de Beaumont O; Arvidsson M; Rak S; Moingeon P
    Allergy; 2015 Jul; 70(7):795-804. PubMed ID: 25846209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.